FDA News & Updates

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between September 11, 2023, and October 16, 2023. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between August 9, 2023, and August 14, 2023. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 17, 2023, and June 15, 2023. Read More ›

On June 20, 2023, the FDA approved a new indication for talazoparib, an oral poly (ADP-ribose) polymerase inhibitor, in combination with enzalutamide for homologous recombination repair gene mutation–positive, metastatic castration-resistant prostate cancer. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between February 9, 2023, and April 3, 2023. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between December 9, 2022, and February 3, 2023. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between October 21, 2022, and December 1, 2022. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between August 24, 2022, and September 30, 2022. Read More ›

This section provides a brief overview of new indications for cancer drugs approved by the FDA between June 22, 2022, and August 11, 2022. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 1, 2022, and May 27, 2022. Read More ›